Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Regulation of gene expression in GOT1 midgut carcinoid in nude mice following injection with 177Lu-octreotate

ABSTRACT: The radiolabelled somatostatin analogue 177Lu-octreotate is a promising treatment option for malignant neuroendocrine tumors that overexpress somatostatin receptors. The human small intestine neuroendocrine tumor cell line GOT1 and Medullary thyroid carcinoma model GOT2 have shown promising treatment response to 177Lu-octreotate in xenografted mice. In clinical studies, however, only low cure rates have been achieved to date. In xenografted tumors, the human stromal components have been replaced with mouse stroma, which may have an impact in the treatment response of the xenografts.

ORGANISM(S): Mus musculus

PROVIDER: GSE80021 | GEO | 2017/12/31

SECONDARY ACCESSION(S): PRJNA317644

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic profiling of human GOT1 and GOT2 tumor xenografts in Balb/c nude mice following 177Lu irradiation and/or Sonidegib treatment

Project description:The radiolabelled somatostatin analogue 177Lu-octreotate is a promising treatment option for malignant neuroendocrine tumors that overexpress somatostatin receptors. The human small intestine neuroendocrine tumor cell line GOT1 and Medullary thyroid carcinoma model GOT2 have shown promising treatment response to 177Lu-octreotate in xenografted mice. In clinical studies, however, only low cure rates have been achieved to date. In vitro and preclinical in vivo studies have shown that irradiation can up-regulate the expression of somatostatin receptors and thereby give an increased uptake of 177Lu-octreotate. The cellular processes that underlie positive treatment response to 177Lu-octreotate are otherwise largely unknown. Genome-wide analysis of tumor cell responses in this successful mouse model offers a venue to identify critical treatment parameters and to optimize clinical effectiveness of 177Lu-octreotate therapy. Combining 177Lu-octreotate with other anti-tumor agents has also been proposed as a strategy for optimization. Some studies have shown synergistic effects in tumor cell killing and volume reduction The hedgehog signaling pathway is involved in embryonic development and tissue regeneration and can be/is abnormally activated in various cancers. Inhibition of the hedgehog signaling pathway has yielded promising therapeutic effects on NE tumors and may potentially enhance the effects of 177Lu-octreotate treatment in patients.

2017-03-08 | GSE80022 | GEO

RT-qPCR analysis of apoptosis related genes in patient-derived xenografts of small intestine neuroendocrine tumors in Balb/c NM after administration of Lu-177-octreotate, Lu-177-octreotate + A1M and A1M

Project description:This work aimed to examine the regulation of apoptosis-related genes in GOT1 tumors one and seven days after administration of 177Lu-octreotate with and without A1M and of A1M alone. At study start, 22 adult female Balb/c GOT1 tumor-bearing mice were divided into four groups of six animals that received 30 MBq 177Lu-octreotate or 5 mg/kg A1M, or co-treatment with both 177Lu-octreotate and A1M by i.v. injection. Also, a control group was sham-treated with saline. Half of the animals in each treatment and control group were terminated by cardiac puncture one-day post-injection (1 dpi), and the remaining animals were terminated at 7dpi. Tumor tissues were dissected at the time of termination, snap-frozen in liquid nitrogen and stored at -80°C.

2023-04-25 | GSE200449 | GEO

Optimization of 177Lu-octreotate treatment of neuroendocrine tumours

Project description:Optimization of 177Lu-octreotate treatment of neuroendocrine tumours

| PRJNA317642 | ENA

Real-time quantitative PCR analysis of mice kidney after administration of Lu-177-octreotate, Lu-177-octreotate + A1M and A1M

Project description:This work aimed to examine the regulation of apoptosis-related genes in kidney cortex and kindey medulla one and seven days after administration of 177Lu-octreotate with and without A1M and of A1M alone. C57BL/6N mice were injected with either 177Lu-octreotate + PBS, A1M + PBS or 177Lu-octreotate + A1M. Also, a control group was sham-treated with saline. Half of the animals in each treatment and control group were terminated by cardiac puncture one-day post-injection (1 dpi), and the remaining animals were terminated at 7dpi. Kidneys were dissected at the time of termination, snap-frozen in liquid nitrogen and stored at -80°C.

2024-04-01 | GSE200619 | GEO

Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice

Project description:Transcriptomic profiling of normal mouse kidney cortex and medulla following 177Lu irradiation

2014-03-05 | GSE44762 | GEO

Biomarkers for radiation-induced renal toxicity following 177Lu-octreotate administration in mice

Project description:Transcriptomic profiling of normal mouse tissue and blood following 177Lu irradiation

2015-08-31 | GSE54674 | GEO

Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice

Project description:Transcriptomic profiling of normal mouse kidney cortex and medulla following 177Lu irradiation Total RNA was isolated from fresh-frozen tissue samples

2014-03-05 | E-GEOD-44762 | biostudies-arrayexpress

Biomarkers for radiation-induced renal toxicity following 177Lu-octreotate administration in mice

Project description:Transcriptomic profiling of normal mouse tissue and blood following 177Lu irradiation Total RNA was isolated from fresh-frozen tissue samples

2015-08-31 | E-GEOD-54674 | biostudies-arrayexpress

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Project description:This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

| 2743256 | ecrin-mdr-crc

Mus musculus

Project description:Regulation of gene expression in GOT1 midgut carcinoid in nude mice following injection with 177Lu-octreotate

| PRJNA317644 | ENA